Compare MTN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | CRSP |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 1997 | 2016 |
| Metric | MTN | CRSP |
|---|---|---|
| Price | $136.75 | $48.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $173.17 | $71.95 |
| AVG Volume (30 Days) | 826.2K | ★ 1.7M |
| Earning Date | 03-09-2026 | 02-11-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 7.24 | N/A |
| Revenue | ★ $2,975,101,000.00 | $38,337,000.00 |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $3.98 | $1,478.13 |
| P/E Ratio | $19.33 | ★ N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $126.16 | $30.04 |
| 52 Week High | $175.51 | $78.48 |
| Indicator | MTN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 41.74 |
| Support Level | $135.99 | $46.48 |
| Resistance Level | $145.89 | $50.63 |
| Average True Range (ATR) | 4.95 | 2.56 |
| MACD | 0.88 | -0.36 |
| Stochastic Oscillator | 56.52 | 28.67 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.